ImmunityBioIBRX
About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Employees: 680
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
120% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 20
71% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 41
11% more funds holding
Funds holding: 180 [Q3] → 199 (+19) [Q4]
1.45% more ownership
Funds ownership: 9.86% [Q3] → 11.32% (+1.45%) [Q4]
17% less call options, than puts
Call options by funds: $8.21M | Put options by funds: $9.86M
17% less capital invested
Capital invested by funds: $256M [Q3] → $212M (-$43.8M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Andres Maldonado 16% 1-year accuracy 8 / 51 met price target | 224%upside $8 | Buy Reiterated | 16 Apr 2025 |
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target | 1,115%upside $30 | Buy Maintained | 15 Apr 2025 |
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target | 224%upside $8 | Buy Initiated | 6 Mar 2025 |
Financial journalist opinion
Based on 6 articles about IBRX published over the past 30 days









